Sarepta Therapeutics | SRPT - Ordinary Share Capital


Sarepta Therapeutics reported $105.57M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Alnylam Pharmaceuticals USD 133.44M 1.07M Mar/2026
Amgen USD 540M 1000K Mar/2026
BioCryst Pharmaceuticals USD 213.06M 2.54M Dec/2025
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Capricor Therapeutics USD 57.37M 11.65M Dec/2025
Daiichi Sankyo JPY 1.85B 9K Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Esperion Therapeutics USD 245.22M 39.79M Dec/2025
Gilead Sciences USD 1.24B 1000K Mar/2026
Incyte USD 199.95M 1.49M Mar/2026
Insmed USD 216.52M 2.27M Mar/2026
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
Moderna USD 391M 2M Sep/2025
Nektar Therapeutics USD 20.38M 20.36M Dec/2025
Neurocrine Biosciences USD 100.6M 500K Mar/2026
Novavax USD 162.58M 106K Dec/2025
Pfizer USD 5.7B 13M Mar/2026
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 795.62M 699.54K Dec/2025
Sanofi EUR 1.21B 8.25M Mar/2026
Sarepta Therapeutics USD 105.57M 607K Mar/2026
Tectonic Therapeutic USD 18.74M 25.03K Dec/2025
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vertex Pharmaceuticals USD 254.2M 200K Mar/2026